Table 3. 30-day all-cause readmission rates by follow-up and baseline characteristics.
| NSTEMI | Heart failure | |||
|---|---|---|---|---|
| % | P value | % | P value | |
| Early follow-up | ||||
| Yes | 17.4 | <0.001 | 20.7 | <0.001 |
| No | 28.3 | 31.2 | ||
| Early follow-up with the same physician | ||||
| Yes | 14.4 | <0.001 | 18.1 | <0.001 |
| No | 27.0 | 29.2 | ||
| Early follow-up with a cardiologist | ||||
| Yes | 15.3 | <0.001 | 18.1 | <0.001 |
| No | 23.6 | 26.5 | ||
| Patient Characteristics | ||||
| Sex | ||||
| Male | 18.5 | <0.001 | 23.8 | 0.205 |
| Female | 22.9 | 22.9 | ||
| Age (yr) | ||||
| 18–49 | 11.7 | <0.001 | 18.4 | <0.001 |
| 50–64 | 16.9 | 20.0 | ||
| 65–79 | 21.2 | 23.3 | ||
| 80+ | 25.5 | 25.9 | ||
| Charlson score | ||||
| 0–1 | 12.3 | <0.001 | 17.9 | <0.001 |
| 2–3 | 22.0 | 22.0 | ||
| 4+ | 30.2 | 29.1 | ||
| Medical history | ||||
| Hypertension | ||||
| Yes | 21.1 | <0.001 | 23.7 | 0.086 |
| No | 16.0 | 22.2 | ||
| Diabetes mellitus | ||||
| Yes | 24.3 | <0.001 | 24.8 | <0.001 |
| No | 15.8 | 22.1 | ||
| Myocardial infarction | ||||
| Yes | 22.9 | 0.040 | 26.5 | 0.005 |
| No | 19.5 | 23.0 | ||
| Heart Failure | ||||
| Yes | 30.2 | <0.001 | 25.6 | <0.001 |
| No | 17.9 | 21.6 | ||
| Atrial fibrillation or flutter | ||||
| Yes | 24.7 | 0.005 | 22.4 | 0.090 |
| No | 19.4 | 23.7 | ||
| Peripheral vascular disease | ||||
| Yes | 25.3 | 0.066 | 28.9 | 0.001 |
| No | 19.7 | 23.1 | ||
| Renal disease | ||||
| Yes | 30.3 | <0.001 | 28.6 | <0.001 |
| No | 17.6 | 22.0 | ||
| In-hospital treatment | ||||
| PCI | ||||
| Yes | 13.4 | <0.001 | 17.7 | 0.004 |
| No | 28.8 | 23.5 | ||
| Intensive care unit use | ||||
| Yes | 19.9 | 0.751 | 26.3 | <0.001 |
| No | 20.4 | 22.5 | ||
| Surgery use | ||||
| Yes | 27.4 | <0.001 | 26.5 | 0.069 |
| No | 19.2 | 23.2 | ||
| Length of stay (d) | ||||
| <5 | 14.4 | <0.001 | 19.7 | <0.001 |
| 6–9 | 18.8 | 22.7 | ||
| 10+ | 28.9 | 29.9 | ||
| Baseline medications | ||||
| Aspirin | ||||
| Yes | 19.5 | 0.005 | 22.5 | 0.028 |
| No | 26.2 | 24.1 | ||
| β-Blocker | ||||
| Yes | 19.2 | 0.074 | 21.5 | <0.001 |
| No | 21.3 | 24.5 | ||
| Statin | ||||
| Yes | 17.8 | <0.001 | 21.5 | 0.020 |
| No | 23.0 | 23.7 | ||
| ACEI/ARB | ||||
| Yes | 18.9 | 0.003 | 21.8 | <0.001 |
| No | 22.6 | 25.6 | ||
| Medications within 7 days of discharge | ||||
| Aspirin | ||||
| Yes | 14.4 | <0.001 | 19.4 | <0.001 |
| No | 25.8 | 24.8 | ||
| β-Blocker | ||||
| Yes | 15.1 | <0.001 | 18.1 | <0.001 |
| No | 22.7 | 25.0 | ||
| Statin | ||||
| Yes | 13.8 | <0.001 | 17.0 | <0.001 |
| No | 23.0 | 24.0 | ||
| ACEI/ARB | ||||
| Yes | 15.1 | <0.001 | 17.1 | <0.001 |
| No | 22.6 | 26.2 | ||
| Medications within 14 days of discharge | ||||
| Aspirin | ||||
| Yes | 14.6 | <0.001 | 19.3 | <0.001 |
| No | 31.5 | 25.4 | ||
| β-Blocker | ||||
| Yes | 15.3 | <0.001 | 18.1 | <0.001 |
| No | 24.4 | 25.8 | ||
| Statin | ||||
| Yes | 13.8 | <0.001 | 17.6 | <0.001 |
| No | 25.0 | 24.2 | ||
| ACEI/ARB | ||||
| Yes | 14.6 | <0.001 | 17.0 | <0.001 |
| No | 24.9 | 27.8 | ||
| Low income | ||||
| Yes | 32.7 | 0.001 | 27.9 | 0.059 |
| No | 19.7 | 23.2 | ||
| Rural residence | ||||
| Yes | 21.2 | 0.219 | 23.4 | 0.876 |
| No | 19.5 | 23.3 | ||
| Number of hospitalizations during the past year | ||||
| 0 | 15.5 | <0.001 | 18.2 | <0.001 |
| 1 | 26.0 | 23.4 | ||
| 2+ | 32.0 | 34.0 | ||
| Number of outpatient visits during the past year | ||||
| Low | 14.8 | <0.001 | 20.3 | <0.001 |
| Medium | 19.7 | 23.3 | ||
| High | 25.4 | 26.5 | ||
| Hospital Characteristics | ||||
| Hospital volume | ||||
| Low | 21.2 | 0.041 | 25.5 | <0.001 |
| Medium | 20.6 | 23.4 | ||
| High | 17.9 | 21.0 | ||
| Hospital level | ||||
| Academic medical center | 18.0 | <0.001 | 20.0 | <0.001 |
| Regional | 22.0 | 24.3 | ||
| District | 28.4 | 27.6 | ||
| Teaching | ||||
| Yes | 19.7 | 0.001 | 22.9 | <0.001 |
| No | 36.2 | 26.9 | ||
| Location | ||||
| Taipei | 18.1 | 0.127 | 22.1 | 0.134 |
| Northern | 19.1 | 23.1 | ||
| Central | 20.3 | 24.1 | ||
| Southern | 22.1 | 25.1 | ||
| Kao-Ping | 21.1 | 23.7 | ||
| Eastern | 23.3 | 23.6 | ||
NSTEMI indicates non-ST-segment-elevation myocardial infarction; and PCI, percutaneous coronary intervention.